The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 23, 2007

Primary Completion Date

February 27, 2008

Study Completion Date

February 27, 2008

Conditions
Benign Prostatic Hypertrophy
Interventions
DRUG

Ozarelix

Ozarelix 15 mg will be administered IM on Day 0 and Day 14.

DRUG

Placebo

Placebo will be administered IM on Day 0 and Day 14.

Trial Locations (13)

10016

Jed Kaminetsky, MD, New York

23454

Gregg Eure, MD, Virginia Beach

34474

Ira Klimberg, MD, Ocala

46825

Christopher Steidle, MD, Fort Wayne

63136

Steven Bigg, MD, St Louis

78229

William Fitch, MD, San Antonio

80012

Joel Kaufman, MD, Aurora

83642

Joseph Williams, MD, Meridian

85712

Donald Gleason, MD, Tucson

90048

Alexander Gershman, MD, Los Angeles

91356

Eugene Dula, MD, Tarzana

92653

Jay Young, MD, Laguna Hills

92660

Stephen Auerbach, MD, Newport Beach

All Listed Sponsors
lead

Spectrum Pharmaceuticals, Inc

INDUSTRY

NCT00427219 - The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate | Biotech Hunter | Biotech Hunter